Doxepin – Usages, Side effects, Risk factors, Precautions

by Psychology Roots
45 views
A+A-
Reset

Doxepin – Usages, Side effects, Risk factors, Precautions

Here in this post, we are discussing the “Prozac”. You can read usages, side effects, Risk factors, and warning information.  Keep visiting Psychology Roots.

About Doxepin

Doxepin is an antidepressant TCAs.

Brand name

Doxepin is available with the following brand name.

     Silenor

Doxepin - Usages, Side effects, Risk factors, Precautions

Doxepin – Usages, Side effects, Risk factors, Precautions

Forms of Doxepin

Doxepin is available in the following form

  • Tablets
  • Capsule
  • Oral suspension

Tablets (Selinor) 
Selinor tablets are available in the following doses

  • 3 mg
  • 6 mg

Capsule
Doxepin capsule  is available in the following dose

  • 10 mg
  • 25 mg
  • 50 mg
  • 75 mg
  • 100 mg
  • 150 mg

Oral suspension
The Oral suspension of Doxepin is available in

  • 10mg/mL

Disorder to treat

It is used for the treatment of the following disorder

     Depression/ Anxiety

     Insomnia

Depression/ Anxiety

Doxepin is initiated at a low dose of 25 mg per day and gradually titrated upward every 5-7 days.

Dosage range: Orally 25-300 mg per day up to 150 mg per day as a single dose.

If the dose exceeds 150 mg per day then divide it into every 12hr.

Dosing considerations

Doxepin may be given at bedtime to decrease daytime sedation.

Insomnia (Silenor)

     For Sleep maintenance 3-6 mg Silenor was orally given within 30 minutes before bedtime.

     It should not exceed 6 mg per day.

     For Hepatic impairment/debilitated patients 3 mg orally given within 30

     minutes before bedtime.

Dosing considerations

To minimize the potential for next-day drowsiness, do not take within 3 hr of a meal (AUC increased by 41% and Cmax by 15% when taken with a high-fat meal)

Side effects

There are the following side effects of doxepin

     Sedation, fatigue, weakness, lethargy

     Headache

     Constipation

     Nausea, vomiting

     Dry mouth

     Anxiety

     Leukopenia

     Blurred vision

     Confusion, extrapyramidal symptoms (EPS), dizziness, paresthesia

     Eosinophilia

     Seizure

     Thrombocytopenia

     SIADH

     Tinnitus

     Agranulocytosis

     Increased LFTs

     Rash

     Sweating

     Orthostatic hypotension, ECG changes, tachycardia

     Sexual dysfunction

     Agitation

     Insomnia

Warnings

In short-term studies, antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (<24 years) taking antidepressants for major depressive disorders and other psychiatric illnesses.

This increase was not seen in patients >24 years; a slight decrease in suicidal thinking was seen in adults >65 years.

In children and young adults, risks must be weighed against the benefits of taking antidepressants.

Patients should be monitored closely for changes in behavior, clinical worsening, and suicidal tendencies; this should be done during the initial 1-2 months of therapy and dosage adjustments.

The patient’s family should communicate any abrupt changes in behavior to the healthcare provider.

Worsening behavior and suicidal tendencies that are not part of the presenting symptoms may require discontinuation of therapy.

This drug is not approved for use in pediatric patients.

Pregnancy

There is no increased risk of major birth defects or miscarriage due to doxepin intake during pregnancy. There are risks of poor neonatal adaptation with exposure to drugs during pregnancy.

Neonatal adverse effects

 Neonates exposed to TCAs, including doxepin, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding; such complications can arise immediately upon delivery.

Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These findings are consistent with either direct toxic effects of TCAs or possibly a drug discontinuation syndrome.

Monitor neonates who were exposed to drugs in the third trimester of pregnancy for poor neonatal adaptation syndrome 

Lactation

 According to studies, the presence of drugs and metabolites in human milk; there are reports of excess sedation, respiratory depression, poor sucking and swallowing, and hypotonia in breastfed infants exposed to drugs.

 There is no data on the effects of drugs on milk production; because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during therapy.

 Infants exposed to drugs through breast milk should be monitored for excess sedation, respiratory depression, and hypotonia.

Help Us Improve This Article

Did you find an inaccuracy? We work hard to provide accurate and scientifically reliable information. If you have found an error of any kind, please let us know.
Add comment. we appropriate your effort.

Share with Us

If you have any scale or any material related to psychology kindly share it with us at psychologyroots@gmail.com. We help others on behalf of you.
Follow

Related Posts

Leave a Comment

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.